LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 856

Search options

  1. Article ; Online: Hyo-Kyu Kim (1917-1999): The One Who Constructed Gangnam Severance Hospital and Reformed Yonsei University Health System.

    Kim, Byung Soo

    Yonsei medical journal

    2019  Volume 60, Issue 9, Page(s) 811–815

    Language English
    Publishing date 2019-10-16
    Publishing country Korea (South)
    Document type Editorial
    ZDB-ID 303740-x
    ISSN 1976-2437 ; 0513-5796
    ISSN (online) 1976-2437
    ISSN 0513-5796
    DOI 10.3349/ymj.2019.60.9.811
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.B 944: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Unveiling the Biosimilar Paradox of Oncologists' Perceptions and Hesitations in South Korea: A Web-Based Survey Study.

    Shin, Gyeongseon / Kim, Byung Soo / Kim, Do Yeun / Bae, SeungJin

    BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy

    2024  Volume 38, Issue 2, Page(s) 301–311

    Abstract: Introduction: Biosimilars offer a cost-effective alternative to original biopharmaceuticals with comparable efficacy and safety. The perception and familiarity of prescribers toward biosimilars play a critical role in their market penetration. Yet, few ... ...

    Abstract Introduction: Biosimilars offer a cost-effective alternative to original biopharmaceuticals with comparable efficacy and safety. The perception and familiarity of prescribers toward biosimilars play a critical role in their market penetration. Yet, few studies have explored the perception of oncologists toward biosimilars, much less in Asia.
    Objectives: The objective of this study is to understand barriers of adopting biosimilars among oncologists and explore strategies to promote their use in clinical practice settings.
    Methods: A web-based survey was conducted among Korean oncologists from September to October 2022, assessing their perception of biosimilars and prescribing practices.
    Results: Among the 118 surveyed oncologists, 75.4% (89 out of 118) had previously prescribed biosimilars. When asked about their preference, 48.3% (57 out of 118) of the respondents preferred originators to biosimilars, whereas 16.1% (19 out of 118) favored biosimilars over the originators. The primary reason for preferring the originators was trust in safety and efficacy (94.7%, 54 out of 57). Still, a paradox was noted as 87.0% (47 out of 54) and 85.2% (46 out of 54) of these also acknowledged the comparable efficacy and safety of biosimilars. A relatively small number of the respondents (16.1%, 19 out of 118) did not consider prescribing biosimilars to biologic-naïve patients at all, and up to 56.8% (67 out of 118) expressed reluctance to switch prescriptions from originators to biosimilars. However, 90.7% (107 out of 118) of respondents considered changing their prescription to biosimilars if patients faced financial stress. Concerns regarding the efficacy when switching to biosimilars were expressed by 42.7% (38 out of 89) of oncologists with biosimilar prescribing experience, increasing to 69.0% (20 out of 29) among those without such experience.
    Conclusion: Korean oncologists perceived biosimilars to be as safe and effective as originators. However, there is a notable mismatch between this perception and their prescribing practices, particularly among those who have not prescribed biosimilars before. The financial burden of patients served as a significant driver for prescribing biosimilars, yet marginal price differences between originators and biosimilars may be associated with the low adoption rate of biosimilars in Korea. Active price competition may enhance market penetration of biosimilars.
    MeSH term(s) Humans ; Biosimilar Pharmaceuticals/therapeutic use ; Oncologists ; Surveys and Questionnaires ; Republic of Korea ; Internet
    Chemical Substances Biosimilar Pharmaceuticals
    Language English
    Publishing date 2024-01-12
    Publishing country New Zealand
    Document type Journal Article
    ZDB-ID 1364202-9
    ISSN 1179-190X ; 1173-8804
    ISSN (online) 1179-190X
    ISSN 1173-8804
    DOI 10.1007/s40259-023-00640-3
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 4112: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Efficacy and safety of netupitant/palonosetron in preventing nausea and vomiting in diffuse large B cell lymphoma patients undergoing R-CHOP chemotherapy.

    Kwak, Kunye / Park, Yong / Kim, Byung Soo / Kang, Ka-Won

    Scientific reports

    2024  Volume 14, Issue 1, Page(s) 11229

    Abstract: Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin's lymphoma, for which cyclophosphamide, doxorubicin, vincristine, and prednisone with rituximab(R-CHOP) is one of the standard regimens. Given that R-CHOP is highly emetogenic, ... ...

    Abstract Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin's lymphoma, for which cyclophosphamide, doxorubicin, vincristine, and prednisone with rituximab(R-CHOP) is one of the standard regimens. Given that R-CHOP is highly emetogenic, chemotherapy-induced nausea and vomiting (CINV) prevention is clinically important. However, there is a paucity of studies focusing on these patients. This study aimed to ascertain the effectiveness of an oral fixed-dose combination of netupitant and palonosetron (NEPA) in preventing CINV in patients with DLBCL undergoing first-line R-CHOP chemotherapy. Seventy patients were enrolled in this single-center prospective non-comparative study conducted between November 2020 and May 2023 in South Korea. NEPA was administered 1 h prior to chemotherapy initiation on day 1. The primary endpoint of the study was the complete response rate (no emesis, and no rescue medication) during the acute, delayed, and overall phases, which were assessed over a period of 120 h post-chemotherapy. The complete response rates for NEPA were 90.0% [95% CI 80.5, 95.9] for the acute phase, 85.7% [95% CI 75.3, 92.9] for the delayed phase, and 84.3% [95% CI 73.6, 91.9] for the overall phase, with no-emesis rates (acute: 97.1% [95% CI 97.1, 99.7], delayed: 95.7% [95% CI 88.0, 99.1], overall: 92.9% [95% CI 84.1, 97.6]). NEPA was well tolerated with no severe treatment-emergent adverse events. NEPA exhibited substantial efficacy in mitigating CINV in DLBCL patients undergoing R-CHOP chemotherapy, demonstrating high CR and no-emesis rates, and favorable safety profiles.
    MeSH term(s) Humans ; Lymphoma, Large B-Cell, Diffuse/drug therapy ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Doxorubicin/adverse effects ; Doxorubicin/administration & dosage ; Cyclophosphamide/adverse effects ; Cyclophosphamide/therapeutic use ; Cyclophosphamide/administration & dosage ; Male ; Female ; Middle Aged ; Vincristine/adverse effects ; Vincristine/therapeutic use ; Vincristine/administration & dosage ; Nausea/prevention & control ; Nausea/chemically induced ; Vomiting/prevention & control ; Vomiting/chemically induced ; Rituximab/adverse effects ; Rituximab/therapeutic use ; Rituximab/administration & dosage ; Prednisone/adverse effects ; Prednisone/administration & dosage ; Prednisone/therapeutic use ; Aged ; Palonosetron/therapeutic use ; Palonosetron/administration & dosage ; Adult ; Prospective Studies ; Antiemetics/therapeutic use ; Antiemetics/administration & dosage ; Pyridines/adverse effects ; Pyridines/administration & dosage ; Pyridines/therapeutic use ; Treatment Outcome ; Drug Combinations ; Isoquinolines ; Quinuclidines
    Chemical Substances R-CHOP protocol ; netupitant, palosentron drug combination
    Language English
    Publishing date 2024-05-16
    Publishing country England
    Document type Journal Article
    ZDB-ID 2615211-3
    ISSN 2045-2322 ; 2045-2322
    ISSN (online) 2045-2322
    ISSN 2045-2322
    DOI 10.1038/s41598-024-62057-4
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Book ; Conference proceedings: The Third International Symposium on Treatment of Liver Cancer

    Kim, Byung Soo

    Seoul, Korea, 12 - 13 February 1993

    (Cancer chemotherapy and pharmacology ; 33, Suppl.)

    1994  

    Event/congress International Symposium on Treatment of Liver Cancer (3, 1993, Seoul)
    Author's details guest ed.: Kim, B. S
    Series title Cancer chemotherapy and pharmacology ; 33, Suppl.
    Collection
    Keywords Liver Neoplasms / therapy / congresses ; Combined Modality Therapy / congresses
    Language English
    Size S154 S. : Ill., graph. Darst.
    Publisher Springer
    Publishing place Berlin u.a.
    Document type Book ; Conference proceedings
    HBZ-ID HT006260833
    Database Catalogue ZB MED Medicine, Health

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Shelf markLoan statusLocation
    Zs A 1420 -33,Suppl.- verfügbar in Königswinter Königswinter

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article: CXCR2 inhibition overcomes ponatinib intolerance by eradicating chronic myeloid leukemic stem cells through PI3K/Akt/mTOR and dipeptidylpeptidase Ⅳ (CD26).

    Kim, Ji-Hea / Kang, Ka-Won / Park, Yong / Kim, Byung Soo

    Heliyon

    2023  Volume 9, Issue 11, Page(s) e22091

    Abstract: This study explores the therapeutic potential of targeting CXCR2 in patients afflicted with ponatinib-resistant chronic myeloid leukemia (CML). Ponatinib, a third-generation tyrosine kinase inhibitor (TKI), was initially designed for treating patients ... ...

    Abstract This study explores the therapeutic potential of targeting CXCR2 in patients afflicted with ponatinib-resistant chronic myeloid leukemia (CML). Ponatinib, a third-generation tyrosine kinase inhibitor (TKI), was initially designed for treating patients with CML harboring the T315I mutation. However, resistance or intolerance issues may lead to treatment discontinuation. Additionally, TKIs have exhibited limitations in eradicating quiescent CML stem cells. Our investigation reveals the activation of CXC chemokine receptor 2 (CXCR2) signaling in response to chemotherapeutic stress. Treatment with the CXCR2 antagonist, SB225002, effectively curtails cell proliferation and triggers apoptosis in ponatinib-resistant CML cells. SB225002 intervention also results in the accumulation of reactive oxygen species and disruption of mitochondrial function, phenomena associated with TKI chemoresistance and apoptosis. Furthermore, we demonstrate that activated CXCR2 expression induces the activity of dipeptidylpeptidase Ⅳ (DPP4/CD26), a CML leukemic stem cell marker, and concomitantly inhibits the PI3K/Akt/mTOR pathway cascades. These findings underscore the novel role of CXCR2 in the regulation of not only ponatinib-resistant CML cells, but also CML leukemic stem cells. Consequently, our study proposes that targeting CXCR2 holds promise as a viable therapeutic strategy for addressing patients with CML grappling with ponatinib resistance.
    Language English
    Publishing date 2023-11-09
    Publishing country England
    Document type Journal Article
    ZDB-ID 2835763-2
    ISSN 2405-8440
    ISSN 2405-8440
    DOI 10.1016/j.heliyon.2023.e22091
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Immunomodulation for Tissue Repair and Regeneration.

    Moon, Sangjun / Hong, Jihye / Go, Seokhyeong / Kim, Byung-Soo

    Tissue engineering and regenerative medicine

    2023  Volume 20, Issue 3, Page(s) 389–409

    Abstract: Various immune cells participate in repair and regeneration following tissue injury or damage, orchestrating tissue inflammation and regeneration processes. A deeper understanding of the immune system's involvement in tissue repair and regeneration is ... ...

    Abstract Various immune cells participate in repair and regeneration following tissue injury or damage, orchestrating tissue inflammation and regeneration processes. A deeper understanding of the immune system's involvement in tissue repair and regeneration is critical for the development of successful reparatory and regenerative strategies. Here we review recent technologies that facilitate cell-based and biomaterial-based modulation of the immune systems for tissue repair and regeneration. First, we summarize the roles of various types of immune cells in tissue repair. Second, we review the principle, examples, and limitations of regulatory T (Treg) cell-based therapy, a representative cell-based immunotherapy. Finally, we discuss biomaterial-based immunotherapy strategies that aim to modulate immune cells using various biomaterials for tissue repair and regeneration.
    MeSH term(s) Regeneration ; Immunity ; Biocompatible Materials ; Immunomodulation
    Chemical Substances Biocompatible Materials
    Language English
    Publishing date 2023-03-15
    Publishing country Korea (South)
    Document type Journal Article ; Review ; Research Support, Non-U.S. Gov't
    ZDB-ID 2677535-9
    ISSN 2212-5469 ; 1738-2696
    ISSN (online) 2212-5469
    ISSN 1738-2696
    DOI 10.1007/s13770-023-00525-0
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: Photonic comb-rooted synthesis of ultra-stable terahertz frequencies.

    Shin, Dong-Chel / Kim, Byung Soo / Jang, Heesuk / Kim, Young-Jin / Kim, Seung-Woo

    Nature communications

    2023  Volume 14, Issue 1, Page(s) 790

    Abstract: Stable terahertz sources are required to advance high-precision terahertz applications such as molecular spectroscopy, terahertz radars, and wireless communications. Here, we demonstrate a photonic scheme of terahertz synthesis devised to bring the well- ... ...

    Abstract Stable terahertz sources are required to advance high-precision terahertz applications such as molecular spectroscopy, terahertz radars, and wireless communications. Here, we demonstrate a photonic scheme of terahertz synthesis devised to bring the well-established feat of optical frequency comb stabilization down to the terahertz region. The source comb is stabilized to an ultra-low expansion optical cavity offering a frequency instability of 10
    Language English
    Publishing date 2023-02-11
    Publishing country England
    Document type Journal Article
    ZDB-ID 2553671-0
    ISSN 2041-1723 ; 2041-1723
    ISSN (online) 2041-1723
    ISSN 2041-1723
    DOI 10.1038/s41467-023-36507-y
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article: Implementation of Field-Programmable Gate Array Platform for Object Classification Tasks Using Spike-Based Backpropagated Deep Convolutional Spiking Neural Networks.

    Kakani, Vijay / Li, Xingyou / Cui, Xuenan / Kim, Heetak / Kim, Byung-Soo / Kim, Hakil

    Micromachines

    2023  Volume 14, Issue 7

    Abstract: This paper investigates the performance of deep convolutional spiking neural networks (DCSNNs) trained using spike-based backpropagation techniques. Specifically, the study examined temporal spike sequence learning via backpropagation (TSSL-BP) and ... ...

    Abstract This paper investigates the performance of deep convolutional spiking neural networks (DCSNNs) trained using spike-based backpropagation techniques. Specifically, the study examined temporal spike sequence learning via backpropagation (TSSL-BP) and surrogate gradient descent via backpropagation (SGD-BP) as effective techniques for training DCSNNs on the field programmable gate array (FPGA) platform for object classification tasks. The primary objective of this experimental study was twofold: (i) to determine the most effective backpropagation technique, TSSL-BP or SGD-BP, for deeper spiking neural networks (SNNs) with convolution filters across various datasets; and (ii) to assess the feasibility of deploying DCSNNs trained using backpropagation techniques on low-power FPGA for inference, considering potential configuration adjustments and power requirements. The aforementioned objectives will assist in informing researchers and companies in this field regarding the limitations and unique perspectives of deploying DCSNNs on low-power FPGA devices. The study contributions have three main aspects: (i) the design of a low-power FPGA board featuring a deployable DCSNN chip suitable for object classification tasks; (ii) the inference of TSSL-BP and SGD-BP models with novel network architectures on the FPGA board for object classification tasks; and (iii) a comparative evaluation of the selected spike-based backpropagation techniques and the object classification performance of DCSNNs across multiple metrics using both public (MNIST, CIFAR10, KITTI) and private (INHA_ADAS, INHA_KLP) datasets.
    Language English
    Publishing date 2023-06-30
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2620864-7
    ISSN 2072-666X
    ISSN 2072-666X
    DOI 10.3390/mi14071353
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article ; Online: Effects of a cognitive rehabilitation program based on mnemonic skills and memory compensatory strategies for older adults: A pilot study.

    Kim, Hyerim / Lee, Jimin / Man Chang, Sung / Kim, Byung-Soo

    Medicine

    2022  Volume 101, Issue 31, Page(s) e29581

    Abstract: Background: With the aging of the population, the number of people with age-related memory complaints has also increased. The purpose of this study was to develop a cognitive rehabilitation program based on mnemonic skills and memory compensatory ... ...

    Abstract Background: With the aging of the population, the number of people with age-related memory complaints has also increased. The purpose of this study was to develop a cognitive rehabilitation program based on mnemonic skills and memory compensatory strategies (CRM) and to investigate the effects of CRM in community-dwelling older adults without dementia.
    Methods: This study was an open-label, single-arm, pilot study. We developed a CRM program comprising 8 weekly sessions. The study participants consisted of older adults with normal cognitive function and mild cognitive impairment (MCI). They were recruited from eight dementia counseling centers and one senior welfare center. To assess the effects of CRM, we administered the following tests at baseline and after completion of the program: Subjective Memory Complaints Questionnaire, the Short form of Geriatric Depression Scale, the Euro Quality of life-5 Dimension, and the Consortium to Establish a Registry for Alzheimer's Disease Neuropsychological Assessment Battery.
    Results: Thirty-two participants completed the study. Among older adults with normal cognitive function, CRM showed significant improvement in verbal memory function. Among the older adults with MCI, CRM showed significant improvements in language ability, verbal recognition memory, nonverbal memory, attention, and processing speed.
    Conclusion: CRM improved cognitive function in two distinct populations, older adults with normal cognitive function and older adults with MCI. Additionally, our preliminary findings suggest that older adults with MCI show cognitive improvement in both the trained and non-trained cognitive domains.
    MeSH term(s) Aged ; Alzheimer Disease ; Cognition ; Cognitive Dysfunction ; Humans ; Neuropsychological Tests ; Pilot Projects ; Quality of Life
    Language English
    Publishing date 2022-08-24
    Publishing country United States
    Document type Journal Article
    ZDB-ID 80184-7
    ISSN 1536-5964 ; 0025-7974
    ISSN (online) 1536-5964
    ISSN 0025-7974
    DOI 10.1097/MD.0000000000029581
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ua VI Zs.171: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article: Real-world safety and effectiveness of secukinumab in adult patients with moderate to severe plaque psoriasis: results from postmarketing surveillance in Korea.

    Kim, Byung Soo / Kim, Dong Hyun / Shin, Bong Seok / Lee, Eun-So / Jo, Seong Jin / Bang, Chul Hwan / Yun, Yeojun / Choe, Yong Beom

    Therapeutic advances in chronic disease

    2024  Volume 15, Page(s) 20406223241230180

    Abstract: Background: Secukinumab, a fully human monoclonal antibody, was approved in Korea for the treatment of moderate to severe psoriasis in September 2015.: Objectives: To assess the safety and effectiveness of secukinumab in patients with moderate to ... ...

    Abstract Background: Secukinumab, a fully human monoclonal antibody, was approved in Korea for the treatment of moderate to severe psoriasis in September 2015.
    Objectives: To assess the safety and effectiveness of secukinumab in patients with moderate to severe psoriasis in Korea.
    Design: Multicenter, real-world, noninterventional study conducted over 6 years.
    Methods: Adults with moderate to severe psoriasis were enrolled. Safety was assessed by evaluating adverse events (AEs), treatment-related AEs, and serious AEs (SAEs). Effectiveness was assessed using the change in absolute Psoriasis Area and Severity Index (PASI) score, percentage of patients achieving PASI 75/90/100 and PASI ⩽2; at weeks 12 and 24.
    Results: Overall, 829 and 542 patients were included in the safety and effectiveness sets, respectively. AEs, treatment-related AEs, and SAEs occurred in 29.0%, 9.5%, and 4.1% of patients, with incidence rates of 39.43, 12.98, and 5.59 per 100 patient years, respectively. The absolute PASI score decreased from 16.1 ± 7.1 (baseline) to 1.6 ± 2.4 (week 24), with a similar reduction in biologic-naïve (16.4 ± 7.3 to 1.5 ± 2.2) and biologic-experienced (14.8 ± 5.9 to 2.4 ± 3.2) groups. At week 24, PASI 75/90/100 was achieved by 95.1%, 62.4%, and 24.9% of patients. At week 24, PASI 75/90 were higher in biologic-naïve (96.6%/65.8%) than biologic-experienced patients (88.3%/48.6%), whereas PASI 100 was similar in both cohorts (24.1% and 28.6%). A similar trend in PASI ⩽ 2 was observed in both cohorts.
    Conclusion: Secukinumab showed sustained effectiveness and favorable safety profile in adult patients with moderate to severe psoriasis in Korea.
    Language English
    Publishing date 2024-02-26
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2554816-5
    ISSN 2040-6231 ; 2040-6223
    ISSN (online) 2040-6231
    ISSN 2040-6223
    DOI 10.1177/20406223241230180
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top